Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children

Pediatric Infectious Disease Journal

Volumn 32, Issue 11, 2013, Pages 1208-1216

  Yoshizawa, Kenichi ^a   Ikawa, Kazuro ^a   Ikeda, Kayo ^a   Ohge, Hiroki ^b   Morikawa, Norifumi ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

breakpoint; carbapenem; children; neonate; probability of target attainment

Indexed keywords

CILASTATIN; IMIPENEM;

ADOLESCENT; ARTICLE; BACTERIUM ISOLATE; CHILD; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG URINE LEVEL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NONHUMAN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SCHOOL CHILD; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEADY STATE; STREPTOCOCCUS PNEUMONIAE; URINARY EXCRETION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMIPENEM; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL;

EID: 84886949173     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829b5880     Document Type: Article

References (39)

1. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67:1027-1052.
2. I shiwada N, Niwa K, Tateno S, et al. Pneumococcal endocarditis in children: a nationwide survey in Japan. Int J Cardiol. 2008;123:298-301.
3. Döring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749-767.
4. Paul M, Yahav D, Bivas A, et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010;11:CD005197.
5. European Medicines Agency. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500003066.pdf. Assessed December 21, 2012.
6. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology- drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
7. S ato H, Narita A, Matsumoto K, et al. Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in neonates. Jpn J Antibiot. 1988;41:1657-1670.
8. T oyonaga Y, Sugita M, Hori M, et al. Pharmacokinetic and clinical studies on imipenem/cilastatin sodium in neonates and premature infants. Jpn J Antibiot. 1988;41:1671-1691.
9. O kura K, Haruta T, Kanamoto T, et al. Evaluation of imipenem/cilastatin sodium in neonatal infections. Jpn J Antibiot. 1988;41:1715-1720.
10. Yura J, Kamiya Y, Suzuki T, et al. Pharmacokinetics and clinical evaluation of imipenem/cilastatin sodium in pediatric surgery. Jpn J Antibiot. 1988;41:1721-1730.
11. I wai N, Nakamura H, Miyazu M, et al. Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates. Jpn J Antibiot. 1989;42:1087-1101.
12. M otohiro T, Sakata Y, Oda K, et al. Pharmacokinetic and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants. Jpn J Antibiot. 1989;42:1102-1124.
13. Fujita K, Kakehashi H, Murono K, et al. Clinical and pharmacokinetic evaluation of imipenem/cilastatin sodium in children. Jpn J Antibiot. 1986;39:1681-1692.
14. N agamatsu I, Tateno Y, Wagatsuma Y, et al. Clinical evaluation of imipenem/ cilastatin sodium in children. Jpn J Antibiot. 1986;39:1693-1700.
15. Hirosawa H, Hoshina H, Morikawa Y, et al. Clinical evaluation of imipenem/cilastatin sodium in the pediatric field. Jpn J Antibiot. 1986;39:1733-1744.
16. N akazawa S, Sato H, Narita A, et al. Fundamental and clinical studies with imipenem/cilastatin sodium, a new carbapenem antibiotic, in the field of pediatrics. Jpn J Antibiot. 1986;39:1745-1764.
17. M inamitani M, Hachimori K, Kaneda K. Clinical study on imipenem/ cilastatin sodium in the field of pediatrics. Jpn J Antibiot. 1986;39: 1817-1827.
18. N akashima T, Nakashima S, Hayakawa F, et al. Fundamental and clinical studies on imipenem/cilastatin sodium in the field of pediatrics. Jpn J Antibiot. 1986;39:1828-1846.
19. N ishimura T, Tabuki K, Takashima T, et al. Laboratory and clinical studies of imipenem/cilastatin sodium in the pediatric field. Jpn J Antibiot. 1986;39:1867-1878.
20. Haruta T, Okura K, Kuroki S, et al. Fundamental and clinical evaluation of imipenem/cilastatin sodium in the field of pediatrics. Jpn J Antibiot. 1986;39:1879-1888.
21. M otohiro T, Koga T, Shimada Y, et al. Pharmacokinetic and clinical studies of imipenem/cilastatin sodium in the pediatric field. Jpn J Antibiot. 1986;39:1889-1911.
22. R eed MD, Kliegman RM, Yamashita TS, et al. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother. 1990;34:1172-1177.
23. Jacobs RF, Kearns GL, Trang JM, et al. Single-dose pharmacokinetics of imipenem in children. J Pediatr. 1984;105:996-1001.
24. European Committee on Antimicrobial Susceptibility Testing. MIC distributions. Available at: http://www.eucast.org/mic distributions/. Assessed August 4, 2012.
25. Yoshizawa K, Ikawa K, Ikeda K, et al. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data. Int J Antimicrob Agents. 2012;40:427-433.
26. I kawa K, Morikawa N, Sakamoto K, et al. Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients. Chemotherapy. 2008;54:131-139.
27. M outon JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/ pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55:601-607.
28. N orrby SR, Alestig K, Ferber F, et al. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrob Agents Chemother. 1983;23:293-299.
29. Kropp H, Sundelof JG, Hajdu R, et al. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982;22:62-70.
30. N orrby SR, Alestig K, Björnegard B, et al. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother. 1983;23:300-307.
31. V erpooten GA, Verbist L, Buntinx AP, et al. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol. 1984;18:183-193.
32. S chwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol. 2007;22:1839-1848.
33. Giannoni E, Moreillon P, Cotting J, et al. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother. 2006;50:2563-2568.
34. Gruber WC, Rench MA, Garcia-Prats JA, et al. Single-dose pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother. 1985;27:511-514.
35. N orrby SR, Rogers JD, Ferber F, et al. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother. 1984;26:707-714.
36. S wanson DJ, DeAngelis C, Smith IL, et al. Degradation kinetics of imipenem in normal saline and in human serum. Antimicrob Agents Chemother. 1986;29:936-937.
37. L ee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis. 2010;68:251-258.
38. Jaruratanasirikul S, Sudsai T. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J Antimicrob Chemother. 2009;63: 560-563.
39. C alandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/ cilastatin. Am J Med. 1988;84:911-918.